N(2)-L-alanyl-L-glutaminum
Dipeptiven is a medicine containing a protein compound, administered intravenously as a component of clinical parenteral and/or enteral nutrition, along with salts, trace elements, and vitamins.
Do not use the medicine:
Dipeptiven must be diluted before administration.Dipeptiven is added to another solution administered to the patient. The doctor or nurse will ensure the proper preparation of the solution with Dipeptiven before administering it to the patient.
Before starting to use Dipeptiven, discuss it with your doctor or nurse. In patients using Dipeptiven, the doctor may order regular blood tests to check the patient's health and confirm the proper functioning of Dipeptiven. Experience with the use of Dipeptiven for more than nine days is limited.
Tell your doctor or pharmacist about all medicines the patient is currently taking or has recently taken, as well as any medicines the patient plans to take.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a child, they should consult their doctor or pharmacist before using this medicine. The medicine should not be used during pregnancy and breastfeeding.
Dipeptiven has no effect on the ability to drive and use machines.
This medicine is administered by infusion into a central or peripheral vein (intravenous drip). The dosage is determined by the doctor individually for each patient, depending on their body weight in kilograms and the ability to break down nutritional components and the need for amino acids. The doctor decides on the size of the dose used in a given patient.
The doctor or nurse will monitor the patient's condition during the infusion, so there is little likelihood of administering a higher dose than recommended. However, if the patient believes they have received a higher dose of Dipeptiven than recommended, they should immediately inform their doctor or nurse. Symptoms of overdose may include chills, nausea, and vomiting. In case of any further doubts about using this medicine, consult your doctor or nurse.
Like all medicines, Dipeptiven can cause side effects, although not everybody gets them. They are not known if the medicine is used as recommended.
If any side effects occur, including any side effects not listed in this leaflet, inform your doctor, pharmacist, or nurse. Side effects can be reported directly to the Department of Adverse Reaction Monitoring of Medicinal Products, Medical Devices, and Biocidal Products, Al. Jerozolimskie 181C, 02-222 Warsaw, tel.: +48 22 49 21 301, fax: +48 22 49 21 309, website: https://smz.ezdrowie.gov.pl. By reporting side effects, more information can be collected on the safety of the medicine.
The doctor or nurse is responsible for ensuring the proper storage, use, and disposal of Dipeptiven. Store below 25°C. After opening: use immediately. Store in the original packaging. Unused medicine is not suitable for further use. Do not use this medicine after the expiry date stated on the packaging. The expiry date refers to the last day of the given month. Medicines should not be disposed of via wastewater or household waste containers. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
100 ml of Dipeptiven contains: 20 g of N(2)-L-alanyl-L-glutamine (= 8.2 g L-alanine and 13.46 g L-glutamine). The other ingredient is water for injections.
Dipeptiven is a clear, colorless solution. The packaging of the medicine is a type II colorless glass bottle with a rubber stopper. Package size: 100 ml. For more detailed information, contact the marketing authorization holder or parallel importer.
Fresenius Kabi Deutschland GmbH, Else-Kroner-Strasse 1, D-61346 Bad Homburg v.d.H., Germany
Fresenius Kabi Austria GmbH, Hafnerstrasse 36, A-8055 Graz, Austria
Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź
Delfarma Sp. z o.o., ul. Św. Teresy od Dzieciątka Jezus 111, 91-222 Łódź, Bulgaria export permit number: 20020591
[Information on the trademark]
To ensure safe administration of Dipeptiven, do not exceed the maximum daily dose of 2.5 ml/kg body weight per day (equivalent to 0.5 g N(2)-L-alanyl-L-glutamine). Dipeptiven should be used only as part of clinical nutrition, and its dosage should be adjusted according to the amount of protein/amino acids required. If the patient's clinical condition does not allow for clinical nutrition (e.g., circulatory shock, hypoxia, unstable critically ill patients, severe metabolic acidosis), Dipeptiven should not be administered. When calculating the recommended dose of Dipeptiven, consider the amount of glutamine contained in oral/enteral products taken in combination with parenteral nutrition. It is recommended to regularly monitor liver function tests in patients with stabilized liver failure. Monitor serum electrolyte levels, serum osmolality, water balance, acid-base balance, creatinine clearance, urea levels, as well as liver function tests (alkaline phosphatase, ALT, AST) and potential symptoms of hyperammonemia. The choice of peripheral or central vein depends on the final osmolality of the mixture. Generally, an osmolality of approximately 800 mOsm/l is considered the upper limit for peripheral infusion, but this value varies greatly depending on the patient's age and overall condition, as well as the condition of the peripheral veins. Experience with the use of Dipeptiven for more than nine days is limited.
Infusion solution obtained after mixing Dipeptiven with a pharmaceutically compatible solution. Solutions with an osmolality above 800 mOsm/l should be administered into a central vein. Adult patients: Dipeptiven is used in parenteral or enteral nutrition, or in both parenteral and enteral nutrition. The dosage depends on the severity of the catabolic state and the need for amino acids/protein. During parenteral/enteral nutrition, do not exceed the maximum daily dose of 2 g amino acids/protein per kilogram body weight. In calculations, consider the content of alanine and glutamine in Dipeptiven. The proportion of amino acids from Dipeptiven should not exceed approximately 30% of the total amino acid/protein intake. Dipeptiven is a concentrate for solution for infusion and is not intended for direct administration. Patients receiving parenteral nutrition: The infusion rate depends on the type of carrier solution and should not exceed 0.1 g amino acids/kg body weight per hour. Dipeptiven should be mixed with a compatible amino acid solution or nutritional mixture containing amino acids before administration. Patients receiving enteral nutrition: Dipeptiven should be administered in continuous infusion lasting from 20 to 24 hours a day. During infusion into peripheral veins, Dipeptiven should be diluted to achieve an osmolality ≤ 800 mOsm/l (e.g., 100 ml Dipeptiven + 100 ml physiological saline solution). Patients receiving both enteral and parenteral nutrition: The total daily dose of Dipeptiven should be administered in parenteral nutrition, e.g., by mixing before administration with a compatible amino acid solution or nutritional mixture containing amino acids. The infusion rate depends on the type of carrier solution and should be adjusted according to the proportion of parenteral and enteral nutrition. Duration of use: The duration of use should not exceed 3 weeks.
Examine the container and solution before use. Use only a clear solution free from solid particles, from an undamaged container. For single use only. Unused leftover medicine is not suitable for further use.
The addition of the concentrate to the carrier solution should be performed under aseptic conditions, before administration to the patient. Ensure thorough mixing and pharmaceutical compatibility.
The medicine should be used immediately after opening the bottle.
Dipeptiven should not be stored after mixing with other components.
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.